Biotech bear mar­ket be damned, CAR-T play­er Ar­cel­lx rais­es $123M IPO

The cur­rent biotech bear mar­ket doesn’t mean it’s im­pos­si­ble for a new biotech to have a suc­cess­ful IPO, mere­ly hard­er.

On Fri­day, CAR-T com­pa­ny Ar­cel­lx an­nounced it priced its IPO at $15 per share, rais­ing $123.8 mil­lion.

Al­though $15 was the low end of the com­pa­ny’s pro­posed range and the over­all to­tal falls short of the New York Yan­kees pay­roll-sized hauls even ear­ly-stage biotechs were able to col­lect in the sum­mer and fall of 2020, it still amounts to a sig­nif­i­cant raise by the in­dus­try’s his­toric stan­dards.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER